GRI Key Statistics, Chart & Performance
The current stock price of GRI is 0.528 USD. In the past month the price decreased by -68.76%. In the past year, price decreased by -96.12%.
GRI Latest News, Press Relases and Analysis
GRI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About GRI
Company Profile
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company is headquartered in La Jolla, California and currently employs 3 full-time employees. The company went IPO on 2021-02-10. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Company Info
GRI BIO INC
2223 Avenida De La Playa, Suite 208
La Jolla CALIFORNIA US
Employees: 3
Phone: 16194001171
GRI BIO INC / GRI FAQ
What does GRI BIO INC do?
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company is headquartered in La Jolla, California and currently employs 3 full-time employees. The company went IPO on 2021-02-10. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Can you provide the latest stock price for GRI BIO INC?
The current stock price of GRI is 0.528 USD. The price increased by 0.21% in the last trading session.
What is the dividend status of GRI BIO INC?
GRI does not pay a dividend.
What is the ChartMill technical and fundamental rating of GRI stock?
GRI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is GRI BIO INC (GRI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GRI.
What is GRI BIO INC worth?
GRI BIO INC (GRI) has a market capitalization of 1.73M USD. This makes GRI a Nano Cap stock.
What is the next earnings date for GRI stock?
GRI BIO INC (GRI) will report earnings on 2026-03-12.
GRI Technical Analysis
GRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRI. The financial health of GRI is average, but there are quite some concerns on its profitability.
GRI Financial Highlights
Over the last trailing twelve months GRI reported a non-GAAP Earnings per Share(EPS) of -8.41. The EPS increased by 98.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -275.12% | ||
| ROE | -660.11% | ||
| Debt/Equity | 0 |
GRI Forecast & Estimates
6 analysts have analysed GRI and the average price target is 104.55 USD. This implies a price increase of 19701.14% is expected in the next year compared to the current price of 0.528.